Two new medicines for advanced kidney cancer recommended by EMA

22 July 2016

The European Medicines Agency (EMA) has recommended granting marketing authorizations in the European Union for two medicines for the treatment of advanced renal cell carcinoma (kidney cancer).

Cabometyx (cabozantinib) – from US biotech firm Exelixis (Nasdaq: EXEL) and France’s Ipsen (Euronext: IPN) and Kisplyx (lenvatinib) – from Japanese drug major Eisai (TYO 4523) - are indicated for the treatment of adult patients with advanced renal cell carcinoma who have been previously treated with a vascular endothelial growth factor (VEGF)-inhibitor; Cabometyx is to be used as monotherapy while Kisplyx is for use in combination with everolimus.

Renal cell carcinoma is the most common form of kidney cancer in adults. Advanced renal cell carcinoma includes both metastatic disease and locally advanced renal cell carcinoma that cannot be removed by surgery. Despite the recent approval of new therapies for advanced renal cell carcinoma, many patients who do not respond to the existing treatments have a poor prognosis. Therefore new treatment options are needed.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK